Green Cross Corp (006280.KS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7006280002
Green Cross Corp financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.68 tn KRW | 1.99 tn KRW |
| Gross profit | 481.93 bn KRW | 554.12 bn KRW |
| Operating income | 32.11 bn KRW | 69.15 bn KRW |
| EBIT | -670.49 m KRW | 14.97 bn KRW |
| Net income | -26.28 bn KRW | -4.67 bn KRW |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; and Varicella Vaccin. It has a research and development agreement with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation.
More stocks
- Yunnan Hongxiang Yixintang (002727.SZ)
- ICG Enterprise Trust PLC (ICGT.L)
- Energyvision NV (ENRGY.BR)
- LEGALZOOM.COM, INC. (LZ)
- Clearway Energy, Inc. (CWEN)
- Alpha Tau Medical Ltd (DRTS)
- Tesna Inc (131970.KQ)
- Trainline PLC (TRN.L)
- Tessenderlo Group NV (TESB.BR)
- ASRock Rack Incorporation (7711.TW)
- Finework (Hu Nan) New Energy Technology Co. Ltd. (301232.SZ)
- Vor Biopharma Inc. (VOR)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.